Skip to content
sellWeak10b5-1 plan

Jack Bendheim sold $467k of PAHC

President and CEO at PHIBRO ANIMAL HEALTH CORP. 10,560 shares at an average of $44.19, traded Nov 17, 2025, filed Nov 18, 2025.

Warning score
27
Value
$467k
10,560 shares
Holdings after
49,680
-18% from before
From 52-week low
+175%
low $16.19, close $44.51
From 52-week high
-2%
high $45.27, as of Nov 17, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $467k at market
    +17
  • Share of holdings sold
    Sold 18% of holdings
    +5
  • Cluster
    No other insider selling within 14 days
    0
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -6.6%, 3m +20.9%, 6m -21.5%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PAHCOct 12, 2026 · close 37.43
Since filing Nov 18, 2025: -12.6%SPY +19.1% · excess -31.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-113795, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 14, 2025CConversion
Class A Common Stockindirect: See10b5-1
+55,000$0.00$060,240Nov 18, 2025
Nov 17, 2025SOpen-market sale
Class A Common Stockindirect: See10b5-1
-5,280$44.56$235k54,960Nov 18, 2025
Nov 18, 2025SOpen-market sale
Class A Common Stockindirect: See10b5-1
-5,260$43.82$230k49,700Nov 18, 2025
Nov 18, 2025SOpen-market sale
Class A Common Stockindirect: See10b5-1
-20$44.28$88649,680Nov 18, 2025
Nov 14, 2025CConversion
Class B Common Stockderivativeindirect: See10b5-1
-55,000$0.00$019,991,034Nov 18, 2025

Related signals

Other insiders at PHIBRO ANIMAL HEALTH CORP and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
PAHCbuy
PHIBRO ANIMAL HEALTH CORP
E Thomas Corcoran
director
$318k
10,000 shares
+32%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.0M
18,608 shares
-25%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.1M
21,120 shares
-22%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
21,120 shares
-18%
50Moderate
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
21,120 shares
-55%
37Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$757k
14,080 shares
-27%
40Moderate
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
21,120 shares
-29%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
22,880 shares
-24%
18Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$258k
5,280 shares
-5%
50Moderate
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.1M
21,120 shares
-93%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Jack Bendheim sold $467k of PAHC | InsiderTell